Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.39 |
| ▸ | KRAS | P01116 | 10/20 | 0.38 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.37 |
| ▸ | JAK3 | P52333 | 4/20 | 0.34 |
| ▸ | BTK | Q06187 | 1/20 | 0.34 |
| ▸ | JAK1 | P23458 | 1/20 | 0.33 |
| ▸ | TEAD1 | P28347 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21787323 | 0.84 | PIK3CD (0.44) | PIK3CDMCHR1JAK3BTKTEAD1 | |
| SCHEMBL21787316 | 0.79 | KRAS (0.39) | KRASJAK3BTKJAK1 | |
| SCHEMBL20314878 | 0.78 | KRAS (0.38) | KRASJAK3BTKJAK1TEAD1 | |
| SCHEMBL20326222 | 0.77 | JAK3 (0.44) | KRASJAK3BTKJAK1 | |
| SCHEMBL21610062 | 0.74 | JAK3 (0.40) | KRASJAK3BTKJAK1 | |
| SCHEMBL23537913 | 0.73 | KRAS (0.43) | KRASJAK3BTKJAK1 | |
| SCHEMBL19229786 | 0.73 | TEAD1 (0.35) | KRASJAK3BTKTEAD1 | |
| SCHEMBL24518644 | 0.71 | TDP1 (0.36) | JAK3BTKTEAD1 | |
| SCHEMBL17426256 | 0.70 | BTK (0.40) | KRASJAK3BTKTEAD1 | |
| SCHEMBL19869620 | 0.69 | PIK3CD (0.50) | PIK3CDMCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210403460-A1 | INHIBITORS OF MUTANT ISOCITRATE DEHYDROGENASES AND COMPOSITIONS AND METHODS THEREOF | ISOCURE BIOSCIENCES INC (US) | 2021-12-30 | — | — | US | disclosed |
| US-11149032-B2 | Inhibitors of mutant isocitrate dehydrogenases and compositions and methods thereof | ISOCURE BIOSCIENCES INC. (US) | 2021-10-19 | — | — | US | disclosed |
| US-20200071309-A1 | INHIBITORS OF MUTANT ISOCITRATE DEHYDROGENASES AND COMPOSITIONS AND METHODS THEREOF | ISOCURE BIOSCIENCES INC (US) | 2020-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210403460-A1 | INHIBITORS OF MUTANT ISOCITRATE DEHYDROGENASES AND COMPOSITIONS AND METHODS THEREOF | IDH1, IDH2, IDH3A | PIK3CD 651/4885KRAS 152/4885MCHR1 4761/4885 |
| US-11149032-B2 | Inhibitors of mutant isocitrate dehydrogenases and compositions and methods thereof | IDH1, IDH2, IDH3A | PIK3CD 651/4885KRAS 152/4885MCHR1 4761/4885 |
| US-20200071309-A1 | INHIBITORS OF MUTANT ISOCITRATE DEHYDROGENASES AND COMPOSITIONS AND METHODS THEREOF | IDH1, IDH2, IDH3A | PIK3CD 651/4885KRAS 152/4885MCHR1 4761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.